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assessment of incidence and economic burden of
rotavirus hospitalizations among children < 5 year
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Salem Alkoshi1,3*, Eyal Leshem2, Umesh D Parashar2 and Maznah Dahlui1Abstract
Background: Libya introduced rotavirus vaccine in October 2013. We examined pre-vaccine incidence of rotavirus
hospitalizations and associated economic burden among children < 5 years in Libya to provide baseline data for
future vaccine impact evaluations.
Methods: Prospective, hospital-based active surveillance for rotavirus was conducted at three public hospitals in
two cities during August 2012 - April 2013. Clinical, demographic and estimated cost data were collected from
children <5 hospitalized for diarrhea; stool specimens were tested for rotavirus with a commercial enzyme immunoassay.
Annual rotavirus hospitalization incidence rate estimates included a conservative estimate based on the number of cases
recorded during the nine months and an extrapolation to estimate 12 months incidence rate. National rotavirus disease
and economic burden were estimated by extrapolating incidence and cost data to the national population of children
aged <5 years.
Results: A total of 410 children <5 years of age with diarrhea were enrolled, of whom 239 (58%) tested positive rotavirus,
yielding an incidence range of 418-557 rotavirus hospitalizations per 100,000 children <5 years of age. Most (86%) rotavirus
cases were below two years of age with a distinct seasonal peak in winter (December-March) months. The total cost of
treatment for each rotavirus patient was estimated at US$ 679 (range: 200–5,423). By extrapolation, we estimated 2,948
rotavirus hospitalizations occur each year in Libyan children <5 years of age, incurring total costs of US$ 2,001,662
(range: 1,931,726-2,094,005).
Conclusions: Rotavirus incurs substantial morbidity and economic burden in Libya, highlighting the potential value of
vaccination of Libyan children against rotavirus.
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Rotavirus is a major cause of severe diarrhea and hos-
pitalization among children aged < 5 years worldwide. In
2008, globally rotavirus caused an estimated 453,000
deaths among children in this age group [1]; more than
half of these deaths occurred in sub-Saharan Africa. In
Libya, health service facilities in Libya are publicly* Correspondence: alkushis@yahoo.com
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hospitals provide preventive and curative treatment to
all citizens free of charge. While the Libyan government
encourages the expansion of private health, private fa-
cilities have insufficient infrastructure to provide a full
treatment service to severe diarrhea patients such as
admission for intravenous fluid (IVF). Rotavirus disease
accounted for 24 – 45% of diarrheal hospitalizations among
children <5 during the period 1980-2009 [2,3]. The eco-
nomic burden of rotavirus infections includes hospital
costs, as well as indirect costs incurred by the society [4,5].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Alkoshi et al. BMC Public Health  (2015) 15:26 Page 2 of 6The World Health Organization (WHO) Strategic Advis-
ory Committee on Immunization (SAGE) recommended
adding rotavirus vaccine to all national immunization pro-
grammes, especially where the mortality rate of diarrhea af-
fected up approximately 10% among children aged below 5
years [6-9]. Two live attenuated vaccines have been ap-
proved for global use: RotaTeq (RV5, Merck, Whitehouse
Station, NJ, USA) is a pentavalent (G1, G2, G3, G4, P[8])
human-bovine reassortant vaccine and Rotarix (RV1,
GlaxoSmithKline Biologicals, Rixensart, Belgium) is a mo-
novalent (G1P[8]) vaccine derived from an attenuated hu-
man strain [10,11]. RotaTeq is administered at 2nd, 4th
and 6th months of age, while Rotarix is administered at
2nd and 4th months of age. In 2009, the World Health
Organization recommended the inclusion of rotavirus vac-
cine in the national immunization programs of all countries
globally and particularly in those countries with high child
mortality due to diarrhea [12]. In Libya, a live attenuated
pentavalent vaccine based on a human rotavirus strain
(RV5; RotaTeq™, Merck & Co. Inc., West Point, PA, USA)
was introduced during October 1, 2013.
In February 2011, ongoing rotavirus surveillance activ-
ities in Libya were interrupted due to civil unrest. Our
objective was to re-establish rotavirus surveillance to
provide up-to-date estimates of the baseline pre-vaccine
incidence of rotavirus hospitalizations among children
aged < 5 years, and economic burden, in order to allow
vaccine impact evaluations in the future.
Methods
Study design and setting
We conducted prospective, active, hospital-based sur-
veillance for rotavirus-associated diarrheal hospitalizations
among children < 5 years of age at three hospitals in two
cities in Northwest Libya during the 9-month period
from August 2012 to April 2013. These 3 hospitals are
the only hospitals for treatment of severe diarrhea pa-
tients in the two cities, Khoms (estimated population
235,894) and Zliten (estimated population 239,860), which
include a combined catchment population of 57,180 chil-
dren aged < 5 years [13].
Surveillance and data collection
Children <5 years of age with diarrhea symptoms (three
or more instances of liquid stool in a day) who sought
therapy in the pediatric ward at the study hospitals wereTable 1 Conservative estimated number of rotavirus hospital
Place of study Population <5
years
Estimated number of rotavirus
(95% confidence interval)
Conservative estimate
Zliten and Khoms 57,180 239
Libya 705,190 2,948 (2,845-3,084)identified and parental/guardian consent was obtained.
Trained nurses collected stool samples from the suspected
patients, whereas the staff researcher collected the demo-
graphic, clinical and economic data from patient’s files.
The stool samples were transferred to the national labora-
tory at the National Center for Diseases Control (NCDC)
where an enzyme immunoassay (ProSpect Rotavirus Test,
Oxoid Ltd, UK) was used to detect Group A rotavirus.
Treatment cost of hospitalized rotavirus patients was cal-
culated from perspectives of hospital (direct cost) and pa-
tient (indirect cost). Hospital cost was conducted only in
Zliten hospital because all studied hospitals are reimbursed
by the same source, Ministry of health and covered closely
similar population. Hospital cost included three compo-
nents: bed-day (Per Diem), medication and laboratory in-
vestigation tests. The cost of bed-day in the hospital
includes the cost of staff salaries and the hotel cost, con-
sisting of furniture, foods, laundry, disposal, cleaning, oper-
ation and maintenance. The cost of bed-day was calculated
by dividing annual expenditure at the pediatric ward (US$
983,015) by the number of patient’s days in the pediatric
ward (accounted at 8,470 patient days in 2012). The cost of
bed-day in the pediatric ward was provided from the finan-
cial management at the Zliten hospital during 2012. Medi-
cation cost was obtained from the central pharmacy, which
was calculated separately for each patient, and the cost of
laboratory tests were provided by the main laboratory in
the hospital.
Several cost elements from the patient perspective
were obtained from parents, including 1) the transpor-
tation cost for trips to the hospital when bringing or
visiting the admitted patient; 2) household cost of ex-
penditures related to the treatment of hospitalized rota-
virus patients such as hygiene items for baby such as
diapers; and 3) lost income of caregivers during the pa-
tient’s illness.
Statistical analysis
We compared demographic and clinical characteristics of
children hospitalized due to rotavirus diarrhea (stool tested
positive for rotavirus) and diarrhea-hospitalizations not as-
sociated with rotavirus (tested negative for rotavirus). The
annual incidence of rotavirus hospitalizations was calcu-
lated by dividing the number of rotavirus diarrhea hospi-
talizations by the number of children < 5 years of age
residing in the catchment area of studies hospitals. Weizations
hospitalizations Annual estimated incidence/100,000 of rotavirus

















Figure 1 Age distribution of positive and negative rotavirus cases association with hospitalization.
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number of cases during the 9 months of enrolment as nu-
merator (not inflating the number of rotavirus hospitaliza-
tions) to calculate annual incidence. Importantly, the
historical months of the peak rotavirus season in Libya
were captured during the 9 months of enrollment. Lastly,
to estimate the annual number of rotavirus hospitalization
countrywide and their associated costs, the conservative
incidence and costs of rotavirus hospitalization from this
study was extrapolated to the national population of
705,190 children <5 years of age in 2012 in Libya.
Data was analyzed by SPSS version 16. Chi-Square and
P values <0.05 were considered statistically significant.
Statistical tests were Chi-Square, X2 and t-test to obtain
the outcomes such as mean, range and standard deviation.
ANOVA or Mann–Whitney’s test were used to make a











Figure 2 Monthly distribution of positive and negative rotavirus caseMean, range and standard deviation were identified in
economic data.
Ethics
University of Malaya Medical Ethics Committee (IRP -
908.6), NCDC in Libya, and study hospitals provided
ethical clearance to conduct the study.
Results
A total of 410 children hospitalized due to diarrhea were
enrolled, of whom 239 (58%) tested positive for rotavirus.
Based on the catchment population in the studied hospitals
(57,180 children aged < 5 years) in 2012, the unadjusted
(conservative) incidence rate of rotavirus associated with
hospitalization in the studied hospitals during the study
period (9 months) was 418 per 100,000 (95% confidence
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tion of Libya (705,190 children aged <5 years) was yielded
an estimate of 2,948 (95% confidence interval, 2,845-3,048)
national hospitalized rotavirus patients associated with
hospitalization in 2012. Most (86%) patients with rotavirus
diarrhea patients were under two years of age (Figure 1)
and the disease showed a distinct winter seasonal peak
during the months from December to March (Figure 2).
Compared with rotavirus-negative patients, those who
were rotavirus-positive were significantly more likely
to suffer severe dehydration and vomiting (Table 2).
Median duration of hospitalization of rotavirus patients
was 3 days (range 1-15) as compared with 2 days (range
1-13) among rotavirus negative patients (p = 0.05), and
nearly all patients receive intravenous fluids. No deaths
were reported.Table 2 Basic characteristics of positive and negative
rotavirus diarrhea associated with hospitalization below






No. (%) No. (%)
Rotavirus Cases 239 (58) 171 (42) 0.001
Places of Study
(Districts)
Zliten 118 (49) 71 (42) 0.116
Khoms 121 (51) 100 (58)
Gender
Male 140 (59) 99 (58) 0.921
Female 101 (41) 70 (42)
Place of Living
Urban 62 (26) 42 (25) 0.752
Rural 177 (74) 129 (75)
Duration of Symptoms
<2 Weeks 233 (97) 165 (96) 0.810
2 weeks and Above 6 (3) 6 (4)
Length of Hospital Stay 0.000
<7 Days 227 (95) 237 (99)
8 Days and Above 12 (5) 2 (1)
Fever 154 (64) 118 (69) 0.335
Vomiting 233 (97) 146 (85) 0.000
Dehydration Degree 0.022
Severe Dehydration 97 (41) 57 (33)
Moderate
Dehydration
138 (58) 102 (60)
No Dehydration 4 (2) 12 (7)
Rehydration Treatment
Treatment with IVF 237 (99) 168 (98) 0.404
Treatment with ORT 2 (1) 3 (2)Treatment costs
From the hospital perspective, the total expenditure to
treat each rotavirus patient in the hospital was calculated
to be US$ 488 (Intra quartile range [IQR], 318-541), the
mean cost for each bed-day (Per Diem) was US$ 116
(Table 3), and the mean cost of medication was US$ 108
(IQR, 43-94). The most expensive medications were
intravenous fluids and antibiotics which were given to
99% and 56% of rotavirus patients, respectively.
From the family perspective, the mean cost for each
hospitalized patient was approximately US$ 191 (IQR,
74-220). Family costs combined with hospital costs
yielded an overall cost to treat each rotavirus patient of
US$ 679 (IQR, 476-737).
Overall, hospital costs comprised 72% of the total ex-
penditure, and family cost made up 28%. Hospital cost
included bed-day (51%), medication (16%) and labora-
tory investigations (5%). Considering the family cost,
transportation, household costs, and lost incomes were
12%, 10% and 6% of total cost, respectively (Table 4).
National burden and costs of rotavirus hospitalization in
Libya
Applying the conservative incidence rate for one year of
surveillance yielded an estimate of 2,948 rotavirus hospi-
talizations annually in Libyan children <5 years of age.
Combining these burden figures with cost data yielded a
national economic burden of US$ 2,001,692 (range:
1,931,726-2,094,005).
Discussion
Our prospective, active, hospital-based surveillance for
rotavirus shows that, prior to rotavirus vaccine intro-
duction, 58% of diarrheal hospitalizations among chil-
dren < 5 years of age in Northwest Libya were caused by
rotavirus. Each rotavirus hospitalization incurred a total
cost of US$ 679, of which 72% were costs of hospitalTable 3 Variables used to calculate the per diem (Bed-Day)
cost for hospitalized patients at Zliten Public Hospital, in
2012
Variable Baseline Source
Per Diem Cost (Bed-Day)
Staff Salaries (US$) 752,266 (77%) Zliten Hospital Management
Hotel Cost (US$) 230,750 (23%) Zliten Hospital Management
Total Per Diem Cost (US$) 983,015
Average Length of Hospital
Stay
3.02 days This Study
Total Bed-Days at Pediatric
Ward
8,470 days Zliten Hospital Management
Costs per Day for each
Patient (US$)
116 Zliten Hospital Management
Hotel Cost includes: Furniture, Equipment, Foods, Laundry, Disposal, Cleaning,
Operation and Maintenance Costs.
Table 4 Treatment cost for hospitalized children
associated with rotavirus diarrhea per each patient
Variable Mean cost (US$) % SD (US$) Range (US$)
Hospital perspective
Per diem 349.31 51% 202.53 57–1,736
Medication 107.73 16% 214.76 14–2,787
Laboratory Tests 31.16 5% 10.62 14–92
Total 488.12 72% 427.91 85–4,615
Patient perspective
Transportation 78.42 12% 69.61 8–773
Household 70.09 10% 69.46 16–472
Lost income 42.37 6% 143.69 0–1,223
Total 190.88 28% 282.77 25–2,470
Overall Total 678.99 499.12 200–5,423
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3000 hospitalizations for rotavirus diarrhea occur each
year in Libyan children 5 years of age or 1 in 50 children
born each year is hospitalized for rotavirus by age 5, in-
curring total costs of US$ 2,001,662. This tremendous
morbidity and economic burden highlights the potential
value of vaccination of Libyan children against rotavirus.
Reports from Libya during the period 1980-2009 showed
a rotavirus detection rate of 24% to 45% among children <5
years of age hospitalized with diarrhea [2,3,14-19], which
were slightly lower compared with our data. This difference
may have resulted from not including 3 months in our
study during which rotavirus rates are usually lower,
thereby increasing the proportion of rotavirus cases among
the studied population; however, the detection rate of rota-
virus in our study is also similar to other regional countries
such as Oman (70%) and Iran (58%) [2]. Characteristics of
rotavirus infection such as vulnerable ages to the disease,
season of increased infection, difference in gender (male
and female) and places of residence (urban and rural areas)
were also comparable to previous reports of rotavirus dis-
ease in Libya [3,14,17-19].
Previous studies have not assessed the economic bur-
den of rotavirus hospitalizations in Libya. Hospital costs
in this study represented 72% of total costs of disease,
which was higher than that reported in the U.S (66%)
[20], but lower than in Brazil (86%) [21]. Lost income of
caretaker in Hong Kong represented 10% of monthly in-
come [22], while it was about 7% in Libya. These data il-
lustrate the substantial economic burden of rotavirus on
both the health care system and families.
Our study has some limitations. Notably, we had planned
to continue surveillance for collection of data for at least
one full calendar year; however, due to the political and se-
curity situation after the Libyan revolution, the study was
interrupted in April 2013. Since the 3 months of data that
we were not able to capture were late spring/summermonths with lower rotavirus prevalence in previous years
[23]. Also, since we conducted surveillance in only 2 cities
in Libya, our findings may not be representative of the en-
tire population. Nevertheless, these are among two of the
large cities in Libya and their population structure and
composition is similar to the rest of the country.
Conclusion
We documented pre-vaccine incidence of rotavirus hos-
pitalization in Libyan children and their associated costs
to provide baseline data for future vaccine impact evalua-
tions. Further studies of rotavirus disease burden among
hospitalized children, in the form of active hospital based
surveillance in Libya, will be crucial to understand the ef-
fect of introducing the vaccine into national childhood
immunization, to provide scientific evidence for continued
immunization efforts and identification of barriers for vac-
cine impact and effectiveness [24,25].
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